Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RNAC Stock Forecast 2025-2026
$9.90
Current Price
$256.78M
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RNAC Price Targets
+324.2%
To High Target of $42.00
+304.0%
To Median Target of $40.00
+122.2%
To Low Target of $22.00
RNAC Price Momentum
-20.4%
1 Week Change
-7.2%
1 Month Change
-53.2%
1 Year Change
-44.7%
Year-to-Date Change
-76.4%
From 52W High of $41.87
+11.9%
From 52W Low of $8.85
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cartesian (RNAC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RNAC and similar high-potential opportunities.
Latest RNAC Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, RNAC has a bullish consensus with a median price target of $40.00 (ranging from $22.00 to $42.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $9.90, the median forecast implies a 304.0% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 324.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RNAC Analyst Ratings
6
Buy
2
Hold
0
Sell
RNAC Price Target Range
Low
$22.00
Average
$40.00
High
$42.00
Current: $9.90
Latest RNAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RNAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 8, 2025 | Needham | Gil Blum | Buy | Maintains | $40.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $40.00 |
| Apr 9, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $40.00 |
| Mar 13, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Jan 28, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
| Jan 27, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Jan 13, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Dec 19, 2024 | BTIG | Julian Harrison | Buy | Initiates | $42.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Dec 3, 2024 | Needham | Buy | Reiterates | $0.00 | |
| Nov 25, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Nov 8, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $41.00 |
| Oct 16, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Sep 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
| Aug 12, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $45.00 |
| Aug 9, 2024 | Needham | Gil Blum | Buy | Maintains | $41.00 |
| Aug 6, 2024 | TD Cowen | Tyler Van Buren | Buy | Initiates | $0.00 |
Cartesian Therapeutics Inc. (RNAC) Competitors
The following stocks are similar to Cartesian based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cartesian Therapeutics Inc. (RNAC) Financial Data
Cartesian Therapeutics Inc. has a market capitalization of $256.78M with a P/E ratio of 0.0x. The company generates $34.17M in trailing twelve-month revenue with a -112.1% profit margin.
Revenue growth is -81.2% quarter-over-quarter, while maintaining an operating margin of -1,989.9% and return on equity of +1,138.3%.
Valuation Metrics
Market Cap
$256.78M
Enterprise Value
$90.58M
P/E Ratio
0.0x
PEG Ratio
-2.8x
Price/Sales
7.5x
Growth & Margins
Revenue Growth (YoY)
-81.2%
Gross Margin
N/A
Operating Margin
-1,989.9%
Net Margin
-112.1%
EPS Growth
-109.2%
Financial Health
Cash/Price Ratio
+70.2%
Current Ratio
12.3x
Debt/Equity
-2.1x
ROE
+1,138.3%
ROA
-7.6%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Cartesian Therapeutics Inc. (RNAC) Business Model
About Cartesian Therapeutics Inc.
What They Do
Develops RNA-engineered cell therapies for diseases.
Business Model
The company employs a proprietary RNA Armory platform to create RNA-modulated cell therapies aimed at treating cancer, autoimmune disorders, and respiratory conditions. By advancing these therapies through various stages of clinical development, Cartesian Therapeutics generates revenue through partnerships, grants, and potential future product sales.
Additional Information
Their innovative approach could significantly impact the biomedical sector by providing more targeted and personalized treatment options. The company is positioned in a growing market focused on biotechnological innovations, contributing to the scientific understanding of RNA technology in medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
66
CEO
Dr. Carsten Brunn Ph.D.
Country
United States
IPO Year
2016
Website
www.cartesiantherapeutics.comCartesian Therapeutics Inc. (RNAC) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,077.14% and 6.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
4 days ago
Quick Summary
Phase 3 AURORA trial of Descartes-08 for myasthenia gravis set to begin in Q2 2025, following positive results from the Phase 2b trial showing sustained benefits at 12 months.
Why It Matters
The initiation of the Phase 3 trial for Descartes-08 suggests potential market expansion and revenue growth for the company, indicating strong future performance and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cartesian Therapeutics granted options to five new employees for 27,700 shares at $12.27 each, vesting over four years. The options have a ten-year term, under Nasdaq Rule 5635(c)(4).
Why It Matters
Granting stock options to new employees can indicate confidence in the company's future and align employee interests with shareholder value, potentially influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Descartes-08 therapy led to sustained deep responses in participants, with an average 4.8-point reduction in MG-ADL at 12 months post-treatment.
Why It Matters
Sustained therapeutic benefits from Descartes-08 indicate potential for strong market demand and revenue growth in biotech, influencing investment decisions in the sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
1 month ago
Quick Summary
Cartesian Therapeutics (NASDAQ: RNAC) will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025, at 2:15 p.m. ET.
Why It Matters
Participation in the Needham Virtual Healthcare Conference highlights Cartesian Therapeutics' visibility and potential for investment interest, crucial for funding and partnerships in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Retirement planning can be challenging, but having a financial expert to assist with achieving goals can ease the process.
Why It Matters
The presence of financial experts can enhance retirement planning, potentially leading to better investment decisions and improved financial security for individuals.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Cartesian Therapeutics granted a new employee an option to purchase 2,650 shares at $17.50, vesting over four years. The award supports recruitment and complies with Nasdaq rules.
Why It Matters
The stock option grant reflects Cartesian Therapeutics' commitment to attracting talent, signaling confidence in future growth, which can positively influence investor sentiment and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RNAC Stock
What is Cartesian Therapeutics Inc.'s (RNAC) stock forecast for 2025?
Based on our analysis of 9 Wall Street analysts, Cartesian Therapeutics Inc. (RNAC) has a median price target of $40.00. The highest price target is $42.00 and the lowest is $22.00.
Is RNAC stock a good investment in 2025?
According to current analyst ratings, RNAC has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RNAC stock?
Wall Street analysts predict RNAC stock could reach $40.00 in the next 12 months. This represents a 304.0% increase from the current price of $9.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cartesian Therapeutics Inc.'s business model?
The company employs a proprietary RNA Armory platform to create RNA-modulated cell therapies aimed at treating cancer, autoimmune disorders, and respiratory conditions. By advancing these therapies through various stages of clinical development, Cartesian Therapeutics generates revenue through partnerships, grants, and potential future product sales.
What is the highest forecasted price for RNAC Cartesian Therapeutics Inc.?
The highest price target for RNAC is $42.00 from Julian Harrison at BTIG, which represents a 324.2% increase from the current price of $9.90.
What is the lowest forecasted price for RNAC Cartesian Therapeutics Inc.?
The lowest price target for RNAC is $22.00 from at , which represents a 122.2% increase from the current price of $9.90.
What is the overall RNAC consensus from analysts for Cartesian Therapeutics Inc.?
The overall analyst consensus for RNAC is bullish. Out of 9 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $40.00.
How accurate are RNAC stock price projections?
Stock price projections, including those for Cartesian Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:19 PM UTC